Bupi Yishen Formula Versus Losartan for Non-Diabetic Stage 4 Chronic Kidney Disease: A Randomized Controlled Trial

Chinese herbal medicine (CHM) might have benefits in patients with non-diabetic chronic kidney disease (CKD), but there is a lack of high-quality evidence, especially in CKD4. This study aimed to assess the efficacy and safety of Bupi Yishen Formula (BYF) vs. losartan in patients with non-diabetic C...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Front Pharmacol
Hauptverfasser: Mao, Wei, Yang, Nizhi, Zhang, Lei, Li, Chuang, Wu, Yifan, Ouyang, Wenwei, Xu, Peng, Zou, Chuan, Pei, Chunpeng, Shi, Wei, Zhan, Jihong, Yang, Hongtao, Chen, Hongyu, Wang, Xiaoqin, Tian, Yun, Yuan, Fang, Sun, Wei, Xiong, Guoliang, Chen, Ming, Guan, Jianguo, Tang, Shuifu, Zhang, Chunyan, Liu, Yuning, Deng, Yueyi, Lin, Qizhan, Lu, Fuhua, Hong, Weihong, Yang, Aicheng, Fang, Jingai, Rao, Jiazhen, Wang, Lixin, Bao, Kun, Lin, Feng, Xu, Yuan, Lu, Zhaoyu, Su, Guobin, Zhang, La, Johnson, David W, Zhao, Daixin, Hou, Haijing, Fu, Lizhe, Guo, Xinfeng, Yang, Lihong, Qin, Xindong, Wen, Zehuai, Liu, Xusheng
Format: Artigo
Sprache:Inglês
Veröffentlicht: Frontiers Media S.A. 2021
Schlagworte:
Pharmacology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7941267/
https://ncbi.nlm.nih.gov/pubmed/33708125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.627185
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge